Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1

G. Cirino, C. Cicala, L. Sorrentino, G. Ciliberto, G. Arpaia, M. Perretti, R. J. Flower

Research output: Contribution to journalArticle

Abstract

An acetylated polypeptide corresponding to residues 2-26 of human lipocortin 1 was synthesized and the anti-inflammatory activity assessed in three models of acute inflammation in rat and mouse. In the carrageenin rat paw oedema test, the peptide produced a maximal inhibition of approximately 41% at the 3 h time point with a 10 μg dose. When rat paw oedema was induced by the injection of venom phospholipase A2, the peptide produced a significant inhibition (31%) at the top dose of 20 μg per paw. In the mouse air-pouch model, systemic treatment with the peptide produced a dramatic reduction in cytokine-induced leukocyte migration with an ID50 of approximately 40 μg per mouse. The N-terminal peptide 2-26 shares the actions of lipocortin 1 in these acute models of inflammation.

Original languageEnglish
Pages (from-to)573-574
Number of pages2
JournalBritish Journal of Pharmacology
Volume108
Issue number3
Publication statusPublished - 1993

Fingerprint

Annexin A1
Anti-Inflammatory Agents
Peptides
Edema
Inflammation
Carrageenan
Phospholipases A2
Venoms
Leukocytes
Air
Cytokines
Injections

Keywords

  • Acute inflammation
  • Anti-inflammatory actions
  • Lipocortin 1/annexin 1
  • N-terminus

ASJC Scopus subject areas

  • Pharmacology

Cite this

Cirino, G., Cicala, C., Sorrentino, L., Ciliberto, G., Arpaia, G., Perretti, M., & Flower, R. J. (1993). Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1. British Journal of Pharmacology, 108(3), 573-574.

Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1. / Cirino, G.; Cicala, C.; Sorrentino, L.; Ciliberto, G.; Arpaia, G.; Perretti, M.; Flower, R. J.

In: British Journal of Pharmacology, Vol. 108, No. 3, 1993, p. 573-574.

Research output: Contribution to journalArticle

Cirino, G, Cicala, C, Sorrentino, L, Ciliberto, G, Arpaia, G, Perretti, M & Flower, RJ 1993, 'Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1', British Journal of Pharmacology, vol. 108, no. 3, pp. 573-574.
Cirino G, Cicala C, Sorrentino L, Ciliberto G, Arpaia G, Perretti M et al. Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1. British Journal of Pharmacology. 1993;108(3):573-574.
Cirino, G. ; Cicala, C. ; Sorrentino, L. ; Ciliberto, G. ; Arpaia, G. ; Perretti, M. ; Flower, R. J. / Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1. In: British Journal of Pharmacology. 1993 ; Vol. 108, No. 3. pp. 573-574.
@article{4effe31dec604f1e8d611899958c6431,
title = "Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1",
abstract = "An acetylated polypeptide corresponding to residues 2-26 of human lipocortin 1 was synthesized and the anti-inflammatory activity assessed in three models of acute inflammation in rat and mouse. In the carrageenin rat paw oedema test, the peptide produced a maximal inhibition of approximately 41{\%} at the 3 h time point with a 10 μg dose. When rat paw oedema was induced by the injection of venom phospholipase A2, the peptide produced a significant inhibition (31{\%}) at the top dose of 20 μg per paw. In the mouse air-pouch model, systemic treatment with the peptide produced a dramatic reduction in cytokine-induced leukocyte migration with an ID50 of approximately 40 μg per mouse. The N-terminal peptide 2-26 shares the actions of lipocortin 1 in these acute models of inflammation.",
keywords = "Acute inflammation, Anti-inflammatory actions, Lipocortin 1/annexin 1, N-terminus",
author = "G. Cirino and C. Cicala and L. Sorrentino and G. Ciliberto and G. Arpaia and M. Perretti and Flower, {R. J.}",
year = "1993",
language = "English",
volume = "108",
pages = "573--574",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1

AU - Cirino, G.

AU - Cicala, C.

AU - Sorrentino, L.

AU - Ciliberto, G.

AU - Arpaia, G.

AU - Perretti, M.

AU - Flower, R. J.

PY - 1993

Y1 - 1993

N2 - An acetylated polypeptide corresponding to residues 2-26 of human lipocortin 1 was synthesized and the anti-inflammatory activity assessed in three models of acute inflammation in rat and mouse. In the carrageenin rat paw oedema test, the peptide produced a maximal inhibition of approximately 41% at the 3 h time point with a 10 μg dose. When rat paw oedema was induced by the injection of venom phospholipase A2, the peptide produced a significant inhibition (31%) at the top dose of 20 μg per paw. In the mouse air-pouch model, systemic treatment with the peptide produced a dramatic reduction in cytokine-induced leukocyte migration with an ID50 of approximately 40 μg per mouse. The N-terminal peptide 2-26 shares the actions of lipocortin 1 in these acute models of inflammation.

AB - An acetylated polypeptide corresponding to residues 2-26 of human lipocortin 1 was synthesized and the anti-inflammatory activity assessed in three models of acute inflammation in rat and mouse. In the carrageenin rat paw oedema test, the peptide produced a maximal inhibition of approximately 41% at the 3 h time point with a 10 μg dose. When rat paw oedema was induced by the injection of venom phospholipase A2, the peptide produced a significant inhibition (31%) at the top dose of 20 μg per paw. In the mouse air-pouch model, systemic treatment with the peptide produced a dramatic reduction in cytokine-induced leukocyte migration with an ID50 of approximately 40 μg per mouse. The N-terminal peptide 2-26 shares the actions of lipocortin 1 in these acute models of inflammation.

KW - Acute inflammation

KW - Anti-inflammatory actions

KW - Lipocortin 1/annexin 1

KW - N-terminus

UR - http://www.scopus.com/inward/record.url?scp=0027406026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027406026&partnerID=8YFLogxK

M3 - Article

C2 - 8467352

AN - SCOPUS:0027406026

VL - 108

SP - 573

EP - 574

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 3

ER -